A robust prognostic signature for hormone-positive node-negative breast cancer.

Genome Med. 2013 Oct 11;5(10):92. [Epub ahead of print]


Systemic chemotherapy in the adjuvant setting can cure breast cancer in some patients that would otherwise recur with incurable, metastatic disease. However, since only a fraction of patients would have recurrence after surgery alone, the challenge is to stratify high-risk patients (who stand to benefit from systemic chemotherapy) from low-risk patients (who can safely be spared treatment related toxicities and costs).


Griffith OL, Pepin F, Enache OM, Heiser LM, Collisson EA, Spellman PT, Gray JW

Institute Authors

Obi Griffith, Ph.D.